PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35283454-1 2022 BACKGROUND: Everolimus-based quadruple low calcineurin inhibitor (CNI) maintenance immunosuppression has been shown to be effective in preserving short-term renal function without compromising efficacy or safety after lung transplantation. Everolimus 12-22 calcineurin binding protein 1 Homo sapiens 43-64 35283454-1 2022 BACKGROUND: Everolimus-based quadruple low calcineurin inhibitor (CNI) maintenance immunosuppression has been shown to be effective in preserving short-term renal function without compromising efficacy or safety after lung transplantation. Everolimus 12-22 calcineurin binding protein 1 Homo sapiens 66-69 35283454-3 2022 METHODS: An investigator-initiated 5-y follow-up analysis of the 4EVERLUNG study (NCT01404325), comparing everolimus-based quadruple low CNI with standard triple regimen, was performed. Everolimus 106-116 calcineurin binding protein 1 Homo sapiens 137-140 32633157-0 2020 Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: Insights from the 24 month TRANSFORM study. Everolimus 71-81 calcineurin binding protein 1 Homo sapiens 95-116 32307148-0 2020 Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus). Everolimus 179-189 calcineurin binding protein 1 Homo sapiens 194-215 32317617-0 2020 Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study: Erratum. Everolimus 10-20 calcineurin binding protein 1 Homo sapiens 34-55 32059083-1 2020 AIMS: Invasive haemodynamic profiles at rest and during exercise after heart transplantation (HTx) have never been described in a randomized trial where de novo everolimus (EVR)-based therapy with early calcineurin inhibitor (CNI) withdrawal has been compared with conventional CNI treatment. Everolimus 173-176 calcineurin binding protein 1 Homo sapiens 203-224 32113691-0 2020 Long-Term Effects of the Replacement of Calcineurin Inhibitors With Everolimus and Mycophenolate in Patients With Calcineurin Inhibitor-Related Nephrotoxicity. Everolimus 68-78 calcineurin binding protein 1 Homo sapiens 40-61 30893292-0 2020 Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 33-54 31152476-0 2019 Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Everolimus 67-77 calcineurin binding protein 1 Homo sapiens 90-111 30939587-0 2019 Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNgamma Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation. Everolimus 22-32 calcineurin binding protein 1 Homo sapiens 125-146 31060742-0 2019 Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports. Everolimus 14-24 calcineurin binding protein 1 Homo sapiens 62-83 29722128-8 2018 In conclusion, conversion to a CNI-free everolimus regimen 3 months after kidney transplantation improved long-term graft function, particularly in patients who continued the CNI-free regimen. Everolimus 40-50 calcineurin binding protein 1 Homo sapiens 31-34 29722128-8 2018 In conclusion, conversion to a CNI-free everolimus regimen 3 months after kidney transplantation improved long-term graft function, particularly in patients who continued the CNI-free regimen. Everolimus 40-50 calcineurin binding protein 1 Homo sapiens 175-178 30097996-0 2018 Effect of Age on Conversion to Everolimus with Calcineurin Inhibitor Minimization at A Late Post-Transplant Stage. Everolimus 31-41 calcineurin binding protein 1 Homo sapiens 47-68 30097996-1 2018 PURPOSE: The purpose of this study was to identify the risk factors for everolimus discontinuation in kidney transplant recipients converted to everolimus with calcineurin inhibitor (CNI) minimization at a late post-transplant stage. Everolimus 72-82 calcineurin binding protein 1 Homo sapiens 160-181 30097996-1 2018 PURPOSE: The purpose of this study was to identify the risk factors for everolimus discontinuation in kidney transplant recipients converted to everolimus with calcineurin inhibitor (CNI) minimization at a late post-transplant stage. Everolimus 144-154 calcineurin binding protein 1 Homo sapiens 160-181 30211023-1 2018 This minireview focuses on the current knowledge about the introduction of everolimus (EVL), a mammalian target of rapamycin inhibitor, with calcineurin inhibitor (CNI) elimination or minimization in kidney transplant recipients at a late posttransplant stage. Everolimus 75-85 calcineurin binding protein 1 Homo sapiens 141-162 30211023-1 2018 This minireview focuses on the current knowledge about the introduction of everolimus (EVL), a mammalian target of rapamycin inhibitor, with calcineurin inhibitor (CNI) elimination or minimization in kidney transplant recipients at a late posttransplant stage. Everolimus 87-90 calcineurin binding protein 1 Homo sapiens 141-162 29752413-0 2018 Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 24-45 29752413-1 2018 Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combination with induction therapy and corticosteroids, everolimus with reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) with standard-exposure CNI (MPA arm). Everolimus 11-21 calcineurin binding protein 1 Homo sapiens 38-59 29954336-1 2018 BACKGROUND: Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). Everolimus 67-77 calcineurin binding protein 1 Homo sapiens 28-49 29954336-1 2018 BACKGROUND: Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). Everolimus 67-77 calcineurin binding protein 1 Homo sapiens 51-54 29954336-7 2018 CONCLUSIONS: This analysis of histological findings in the ZEUS study to 5 years after kidney transplantation shows no increase in antibody-mediated rejection under everolimus-based therapy with a lower rate of CNI-related toxicity compared to a conventional CsA-based regimen, and confirms the preponderance of mild BPAR seen in the main study after the early switch to CsA-free everolimus therapy. Everolimus 165-175 calcineurin binding protein 1 Homo sapiens 211-214 28230646-1 2017 BACKGROUND: Albuminuria in maintenance heart transplantation (HTx) is associated with poor renal response when switching to a calcineurin inhibitor (CNI)-lowered or CNI-free immunosuppressive regimen using everolimus (EVR), but the significance of albuminuria associated with EVR treatment after early CNI withdrawal in de novo HTx is unknown. Everolimus 206-216 calcineurin binding protein 1 Homo sapiens 126-147 28878864-3 2017 Initiating EVR early post-LT allows for calcineurin inhibitor (CNI) reduction, thus reducing nephrotoxicity in LT recipients. Everolimus 11-14 calcineurin binding protein 1 Homo sapiens 40-61 28133906-8 2017 In conclusion, early introduction of everolimus at an adequate exposure level with gradual calcineurin inhibitor (CNI) withdrawal after liver transplantation, supported by induction therapy and mycophenolic acid, is associated with a significant renal benefit versus CNI-based immunosuppression but more frequent BPAR. Everolimus 37-47 calcineurin binding protein 1 Homo sapiens 91-112 27915965-7 2017 The mammalian target of rapamycin inhibitors everolimus and sirolimus are preferred due to their complementary mechanisms of action and favorable nephrotoxicity profile, which have opened the way for calcineurin inhibitor reduction/withdrawal in the early posttransplant period. Everolimus 45-55 calcineurin binding protein 1 Homo sapiens 200-221 28107397-1 2017 BACKGROUND: Conversion to everolimus is often used in kidney transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach. Everolimus 26-36 calcineurin binding protein 1 Homo sapiens 89-110 28107397-1 2017 BACKGROUND: Conversion to everolimus is often used in kidney transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach. Everolimus 26-36 calcineurin binding protein 1 Homo sapiens 112-115 28107397-11 2017 CONCLUSIONS: Conversion from CNI to everolimus after kidney transplantation is associated with improved renal function in the first 5 years posttransplant but increases the risk of acute rejection at 1 year posttransplant and may not be well endured. Everolimus 36-46 calcineurin binding protein 1 Homo sapiens 29-32 28104152-0 2017 Experience of Quatro-Therapy With Everolimus to Minimize Calcineurin Inhibitor for Kidney Transplant Recipients. Everolimus 34-44 calcineurin binding protein 1 Homo sapiens 57-78 27067532-0 2016 Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. Everolimus 77-87 calcineurin binding protein 1 Homo sapiens 101-122 27160359-1 2016 BACKGROUND: The 12-month (M) PROTECT study showed that de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)-based immunosuppression to a CNI-free everolimus (EVR)-based regimen showed numerically better renal function. Everolimus 184-194 calcineurin binding protein 1 Homo sapiens 175-178 27160359-11 2016 CONCLUSION: Compared with the CNI-based treatment, EVR-based CNI-free immunosuppression resulted in significantly better renal function and comparable patient and graft outcomes after five-yr follow-up. Everolimus 51-54 calcineurin binding protein 1 Homo sapiens 61-64 26820618-0 2016 Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 33-54 26820618-1 2016 In a randomized, open-label trial, de novo heart transplant recipients were randomized to everolimus (3-6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to weeks 7-11 after transplant, followed by increased everolimus exposure (target 6-10 ng/mL) with cyclosporine withdrawal or standard-exposure cyclosporine. Everolimus 90-100 calcineurin binding protein 1 Homo sapiens 135-156 27234735-1 2016 BACKGROUND: Utilization of everolimus (EVR) has been increasing in recent years for patients undergoing renal transplantation to reduce calcineurin inhibitor (CNI) levels. Everolimus 27-37 calcineurin binding protein 1 Homo sapiens 136-157 27234735-1 2016 BACKGROUND: Utilization of everolimus (EVR) has been increasing in recent years for patients undergoing renal transplantation to reduce calcineurin inhibitor (CNI) levels. Everolimus 39-42 calcineurin binding protein 1 Homo sapiens 136-157 27234736-1 2016 BACKGROUND: Everolimus (EVR) has been used widely for the purpose of reducing the dosage of calcineurin inhibitor (CNI), leading to decreasing CNI nephrotoxicity. Everolimus 12-22 calcineurin binding protein 1 Homo sapiens 92-113 27234736-1 2016 BACKGROUND: Everolimus (EVR) has been used widely for the purpose of reducing the dosage of calcineurin inhibitor (CNI), leading to decreasing CNI nephrotoxicity. Everolimus 24-27 calcineurin binding protein 1 Homo sapiens 92-113 26842532-11 2016 CONCLUSIONS: Everolimus with very low-dose calcineurin inhibitor given immediately after liver transplantation appears safe and effective, achieving a low rejection rate with well-preserved renal function. Everolimus 13-23 calcineurin binding protein 1 Homo sapiens 43-64 26603484-1 2016 Two main everolimus-based strategies have been pursued to facilitate calcineurin inhibitor (CNI) reduction after kidney transplantation: (i) everolimus with reduced CNI exposure from time of transplant and (ii) pre-emptive introduction of everolimus with CNI reduction or withdrawal at some point post-transplant. Everolimus 9-19 calcineurin binding protein 1 Homo sapiens 69-90 25783974-1 2015 Early initiation of everolimus with calcineurin inhibitor therapy has been shown to reduce the progression of cardiac allograft vasculopathy (CAV) in de novo heart transplant recipients. Everolimus 20-30 calcineurin binding protein 1 Homo sapiens 36-57 25783974-3 2015 This 12-month multicenter Scandinavian trial randomized 115 de novo heart transplant recipients to everolimus with complete calcineurin inhibitor elimination 7-11 weeks after HTx or standard cyclosporine immunosuppression. Everolimus 99-109 calcineurin binding protein 1 Homo sapiens 124-145 26031588-0 2015 Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts. Everolimus 26-36 calcineurin binding protein 1 Homo sapiens 50-71 26031588-1 2015 AIM: The aim of this study was to evaluate the effect of tacrolimus (TAC) reduction with everolimus (EVR) addition on the maintenance immunosuppression for the recipients with calcineurin inhibitor arteriolopathy (CNIA). Everolimus 89-99 calcineurin binding protein 1 Homo sapiens 176-197 25873064-3 2015 Several studies have shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy. Everolimus 32-42 calcineurin binding protein 1 Homo sapiens 204-225 25207429-0 2015 Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen. Everolimus 88-98 calcineurin binding protein 1 Homo sapiens 112-133 25207429-0 2015 Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen. Everolimus 88-98 calcineurin binding protein 1 Homo sapiens 135-138 24983307-10 2015 CONCLUSION: The results of this study provide the evidences that (1) the calcineurin inhibitor (CNI) minimization by the introduction of everolimus after 1-month posttransplantation keeps the incidences of acute rejection and additional risks as low as the conventional immunosuppression; (2) it allows minimizing CNI exposure, consequently reducing CNI nephrotoxicity and preserving renal function. Everolimus 137-147 calcineurin binding protein 1 Homo sapiens 73-94 24606320-0 2014 Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 92-113 24932812-1 2014 The mTOR inhibitor everolimus (EVL) can be used for calcineurin inhibitor-sparing immunosuppression in heart transplantation (HTx). Everolimus 19-29 calcineurin binding protein 1 Homo sapiens 52-73 24932812-1 2014 The mTOR inhibitor everolimus (EVL) can be used for calcineurin inhibitor-sparing immunosuppression in heart transplantation (HTx). Everolimus 31-34 calcineurin binding protein 1 Homo sapiens 52-73 24206966-0 2014 Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years. Everolimus 21-31 calcineurin binding protein 1 Homo sapiens 37-58 24206966-3 2014 Few studies have examined everolimus therapy with calcineurin inhibitor (CNI) withdrawal in maintenance heart transplant patients (HTx). Everolimus 26-36 calcineurin binding protein 1 Homo sapiens 50-71 24206966-3 2014 Few studies have examined everolimus therapy with calcineurin inhibitor (CNI) withdrawal in maintenance heart transplant patients (HTx). Everolimus 26-36 calcineurin binding protein 1 Homo sapiens 73-76 24206966-14 2014 CONCLUSIONS: Calcineurin inhibitor-free immunosuppression with everolimus is an effective and safe option in selected maintenance HTx patients. Everolimus 63-73 calcineurin binding protein 1 Homo sapiens 13-34 24128136-9 2013 CONCLUSIONS: Everolimus allows calcineurin inhibitor-reduction and withdrawal after a heart transplant, resulting in improved renal function. Everolimus 13-23 calcineurin binding protein 1 Homo sapiens 31-52 24029254-3 2013 This study aims to evaluate the safety and efficacy of everolimus in renal transplant recipients with calcineurin inhibitor (CNI) withdrawal either due to CAN or cal-cineurin inhibitor toxicity (CNIT). Everolimus 55-65 calcineurin binding protein 1 Homo sapiens 102-123 23621682-0 2013 Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Everolimus 96-106 calcineurin binding protein 1 Homo sapiens 113-134 23422495-0 2013 Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Everolimus 20-30 calcineurin binding protein 1 Homo sapiens 43-64 23230975-1 2013 BACKGROUND: The association between clinical events and everolimus exposure in patients receiving reduced-exposure calcineurin inhibitor therapy is poorly explored. Everolimus 56-66 calcineurin binding protein 1 Homo sapiens 115-136 22958738-1 2012 In this 12-month multicenter Scandinavian study, 78 maintenance heart transplant (HTx) recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) exposure or continued standard CNI-therapy underwent matched virtual histology (VH) examination to evaluate morphological progression of cardiac allograft vasculopathy (CAV). Everolimus 112-122 calcineurin binding protein 1 Homo sapiens 136-157 22890040-3 2012 RECENT FINDINGS: The use of everolimus in pediatric organ transplantation is associated with a decrease in calcineurin inhibitor-related toxicity, better renal function, a low number of acute rejections, and an acceptable side-effect profile. Everolimus 28-38 calcineurin binding protein 1 Homo sapiens 107-128 21631587-1 2012 The mTOR inhibitors (ImTORs) sirolimus (SRL) and everolimus (EVR) have been increasingly used in renal transplantation as part of calcineurin inhibitor (CNI) sparing or avoidance regimens. Everolimus 49-59 calcineurin binding protein 1 Homo sapiens 130-151 22404500-4 2012 EXPERT OPINION: Judging by the more recent trials, it seems that EVL, in association with calcineurin inhibitor (CNI) minimization, provides a well-tolerated regimen with a low risk of rejection and good graft function. Everolimus 65-68 calcineurin binding protein 1 Homo sapiens 90-111 22333403-4 2012 METHODS: This 12-month multicenter Scandinavian study randomized 282 maintenance TTx recipients to everolimus introduction with calcineurin inhibitor (CNI) reduction or standard CNI therapy. Everolimus 99-109 calcineurin binding protein 1 Homo sapiens 128-149 22466910-8 2012 CONCLUSIONS: Elimination of CNI from a de novo regimen of everolimus with low-exposure CNI at one year post-transplant maintained efficacy and led to a non-significant but clinically relevant improvement in renal function, although patients numbers were low (n=30). Everolimus 58-68 calcineurin binding protein 1 Homo sapiens 28-31 22466910-8 2012 CONCLUSIONS: Elimination of CNI from a de novo regimen of everolimus with low-exposure CNI at one year post-transplant maintained efficacy and led to a non-significant but clinically relevant improvement in renal function, although patients numbers were low (n=30). Everolimus 58-68 calcineurin binding protein 1 Homo sapiens 87-90 21911148-5 2011 Conversion to everolimus allowed us to eliminate the calcineurin inhibitor (CNI) in 21% of patients. Everolimus 14-24 calcineurin binding protein 1 Homo sapiens 53-74 21693288-0 2011 Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years" follow-up from the University Hospital Munster. Everolimus 51-61 calcineurin binding protein 1 Homo sapiens 0-21 21693288-0 2011 Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years" follow-up from the University Hospital Munster. Everolimus 63-71 calcineurin binding protein 1 Homo sapiens 0-21 21693288-2 2011 To date, there are only sparse data about long-term calcineurin inhibitor (CNI)-free immunosuppression using everolimus. Everolimus 109-119 calcineurin binding protein 1 Homo sapiens 75-78 21693288-4 2011 Reasons for switching to everolimus were side effects of CNI immunosuppression, such as deterioration of kidney function and recurrent rejection episodes. Everolimus 25-35 calcineurin binding protein 1 Homo sapiens 57-60 21693288-14 2011 CONCLUSION: CNI-free immunosuppression using everolimus is safe, with excellent efficacy in maintenance of heart transplant recipients. Everolimus 45-55 calcineurin binding protein 1 Homo sapiens 12-15 21478817-0 2011 Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. Everolimus 21-31 calcineurin binding protein 1 Homo sapiens 37-58 21478817-1 2011 BACKGROUND: Few studies have examined everolimus therapy with calcineurin inhibitor (CNI) withdrawal in maintenance heart transplant patients. Everolimus 38-48 calcineurin binding protein 1 Homo sapiens 62-83 21478817-1 2011 BACKGROUND: Few studies have examined everolimus therapy with calcineurin inhibitor (CNI) withdrawal in maintenance heart transplant patients. Everolimus 38-48 calcineurin binding protein 1 Homo sapiens 85-88 21478817-2 2011 METHODS: In a prospective, single-arm, single-center study, CNI-treated heart transplant patients were converted to everolimus and were followed up for 24 months. Everolimus 116-126 calcineurin binding protein 1 Homo sapiens 60-63 21478817-11 2011 CONCLUSIONS: CNI-free immunosuppression with everolimus is an effective and safe option in selected heart transplant maintenance patients. Everolimus 45-55 calcineurin binding protein 1 Homo sapiens 13-16 21334736-0 2011 Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 18-39 21334736-2 2011 Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy. Everolimus 71-81 calcineurin binding protein 1 Homo sapiens 128-149 21334736-6 2011 The primary objective was to show better renal function (glomerular filtration rate [GFR]; Nankivell formula) with the calcineurin-inhibitor-free everolimus regimen at 12 months after transplantation. Everolimus 146-156 calcineurin binding protein 1 Homo sapiens 119-140 21162600-10 2011 Even though everolimus may be better tolerated than sirolimus, studies on everolimus for calcineurin inhibitor-free immunosuppression in the pediatric kidney transplant patient population are lacking. Everolimus 74-84 calcineurin binding protein 1 Homo sapiens 89-110 21030905-0 2010 Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Everolimus 72-82 calcineurin binding protein 1 Homo sapiens 96-117 21030905-1 2010 BACKGROUND: Use of the mammalian target of rapamycin inhibitor everolimus with an accompanying reduction in calcineurin inhibitor (CNI) exposure has shown promise in preserving renal function in maintenance thoracic transplant patients, but robust, long-term data are required. Everolimus 63-73 calcineurin binding protein 1 Homo sapiens 108-129 20061999-0 2010 Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 24-45 20061999-1 2010 BACKGROUND: The proliferation signal inhibitor everolimus offers the potential to reduce calcineurin inhibitor (CNI) exposure and alleviate CNI-related nephrotoxicity. Everolimus 47-57 calcineurin binding protein 1 Homo sapiens 89-110 20061999-1 2010 BACKGROUND: The proliferation signal inhibitor everolimus offers the potential to reduce calcineurin inhibitor (CNI) exposure and alleviate CNI-related nephrotoxicity. Everolimus 47-57 calcineurin binding protein 1 Homo sapiens 112-115 20061999-1 2010 BACKGROUND: The proliferation signal inhibitor everolimus offers the potential to reduce calcineurin inhibitor (CNI) exposure and alleviate CNI-related nephrotoxicity. Everolimus 47-57 calcineurin binding protein 1 Homo sapiens 140-143 20061999-11 2010 CONCLUSION: Introduction of everolimus with CNI reduction offers a significant improvement in renal function in maintenance heart and lung transplant recipients. Everolimus 28-38 calcineurin binding protein 1 Homo sapiens 44-47 20050127-1 2010 Data are scarce concerning the calcineurin inhibitor dose reduction required following introduction of everolimus in maintenance heart transplant recipients to maintain stable renal function. Everolimus 103-113 calcineurin binding protein 1 Homo sapiens 31-52 19542890-5 2009 More substantial reduction in CNI levels is safe and effective with the introduction of sirolimus or everolimus. Everolimus 101-111 calcineurin binding protein 1 Homo sapiens 30-33 19715854-1 2009 Whenever graft function is good and proteinuria is under control, many reports describe the efficacy and safety of the conversion to Everolimus (EVL) among stable kidney recepients, simultaneously withdrawing the calcineurin inhibitor (CNI). Everolimus 133-143 calcineurin binding protein 1 Homo sapiens 213-234 18793527-0 2008 Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot study. Everolimus 29-39 calcineurin binding protein 1 Homo sapiens 92-113 18223473-0 2008 Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 82-103 17346627-0 2007 Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months" follow-up. Everolimus 51-61 calcineurin binding protein 1 Homo sapiens 0-21 17346627-0 2007 Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months" follow-up. Everolimus 63-71 calcineurin binding protein 1 Homo sapiens 0-21 17346627-3 2007 This study reports the results of CNI-free immunosuppression using everolimus. Everolimus 67-77 calcineurin binding protein 1 Homo sapiens 34-37 17346627-5 2007 Reasons for switching to everolimus were side effects associated with prior CNI immunosuppression. Everolimus 25-35 calcineurin binding protein 1 Homo sapiens 76-79 17346627-14 2007 CONCLUSION: Preliminary data suggest that CNI-free immunosuppression using everolimus is safe, with excellent efficacy in maintenance heart transplant recipients. Everolimus 75-85 calcineurin binding protein 1 Homo sapiens 42-45 17097956-2 2006 We describe an initial experience among 32 renal transplant recipients who were converted to Everolimus with complete suspension of CNI in two Spanish transplant centers. Everolimus 93-103 calcineurin binding protein 1 Homo sapiens 132-135 16815852-4 2006 Thus, everolimus may play an important role in calcineurin inhibitor (CNI)-sparing regimens for renal transplant recipients. Everolimus 6-16 calcineurin binding protein 1 Homo sapiens 47-68 15880017-0 2005 Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican). Everolimus 117-127 calcineurin binding protein 1 Homo sapiens 13-34 15880017-0 2005 Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican). Everolimus 129-137 calcineurin binding protein 1 Homo sapiens 13-34 15880021-1 2005 BACKGROUND: Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in transplant patients, minimizing risk of nephrotoxicity without loss of immunosuppressive efficacy. Everolimus 12-22 calcineurin binding protein 1 Homo sapiens 82-103 15880021-1 2005 BACKGROUND: Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in transplant patients, minimizing risk of nephrotoxicity without loss of immunosuppressive efficacy. Everolimus 24-32 calcineurin binding protein 1 Homo sapiens 82-103 15093807-10 2004 In addition, there is evidence from studies in renal transplant recipients that everolimus plus reduced exposure cyclosporine is effective and well tolerated-with the regimen having a reduced potential for CNI-related nephrotoxicity and for other CNI-related cardiovascular side effects. Everolimus 80-90 calcineurin binding protein 1 Homo sapiens 206-209 15093807-10 2004 In addition, there is evidence from studies in renal transplant recipients that everolimus plus reduced exposure cyclosporine is effective and well tolerated-with the regimen having a reduced potential for CNI-related nephrotoxicity and for other CNI-related cardiovascular side effects. Everolimus 80-90 calcineurin binding protein 1 Homo sapiens 247-250 33795116-0 2021 Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study). Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 33-54 34216395-0 2021 Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: Two-year results from the subgroup analysis of the TRANSFORM study. Everolimus 0-10 calcineurin binding protein 1 Homo sapiens 23-44